We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

HORIBA Medical

HORIBA ABX designs, develops and distributes worldwide, in vitro diagnostic systems for biological analysis in medica... read more Featured Products: More products

Download Mobile App




New Hematology Analyzer Brings High-Standard Reticulocyte Analysis to a Compact Platform

By LabMedica International staff writers
Posted on 03 Mar 2014
A new, reliable, easy-to-use hematology analyzer with integrated PC eliminates manual methods to enhance laboratory productivity while maintaining standardization.

Horiba Medical division of Horiba UK (Northhampton, UK) now offers the new "Pentra XLR compact 5 part DIFF" hematology analyzer, incorporating full reticulocyte parameters to facilitate the investigation and diagnosis of hemopoiesis and anemia. More...
As the latest addition to the Pentra family, the XLR brings Horiba’s gold standard reticulocyte technology with STAT capabilities to a smaller platform. This makes it well suited for space-restricted laboratories or those with a smaller workload, without compromising on quality.

The new, reliable, easy-to-use analyzer with integrated PC eliminates manual methods to enhance laboratory productivity and ensure standardization of reticulocyte count. The Pentra XLR’s large capacity autoloader and ability to process 80 samples per hour, combined with auto rerun, Customized Dilution Ratio (CDR) and automatic validation, all enable a hands-off approach. Users can thus dedicate valuable time to results analysis and more specialised needs.

Providing a high degree of flexibility, the new Pentra XLR has a microsampling system requiring only 53 µl of blood for FBC and 35 µl for full reticulocyte analysis, making it well suited for pediatric or other small samples. The reticulocyte channel utilizes Thiazole Orange technology, providing a full maturity profile in addition to a highly accurate reticulocyte count. It is also compatible with ABX Pentra ML data management, facilitating simple integration into existing systems.
The new Pentra XLR is built on the same proven reticulocyte technology as Horiba’s higher throughput Pentra analyzers, ensuring quality and full compatibility of results and reagents. With three quality control levels for all parameters, this robust and reliable platform also provides complete data traceability on-board and integrated validation, thus enhancing peace of mind also for the user.

“The Pentra XLR enhances laboratory productivity, flexibility and quality, adding value to any hematology laboratory,” said Cleve Wright, Horiba UK; “By incorporating full reticulocyte analytical capabilities, the Pentra XLR delivers high quality detailed analysis for highly accurate patient diagnosis on a compact platform.”

Related Links:

Horiba Medical



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
New
Drug Testing Assays
Atellica DT 250 Analyzer
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Lead author Professor Chamindie Punyadeera. (Image Credit: Griffith University)

Breath Analysis Shows Promise for Distinguishing Cancerous from Benign Lung Nodules

Lung nodules are frequently detected during imaging, but distinguishing malignant from benign findings can require invasive procedures. Some patients undergo biopsies, bronchoscopy, or surgery before learning... Read more

Molecular Diagnostics

view channel
Image: Skin samples from people with a suspected genetic myopathy were examined for confirmation of disease. Brown spots show abnormal protein buildup inside the nuclei of cells (purple), typical of a type of myopathy called oculopharyngodistal myopathy. (Image Credit: Garvan Institute)

Long-Read Sequencing Test Identifies Genetic Causes in Inherited Muscle Disease

Inherited muscle diseases are highly heterogeneous and often progressive, leaving many patients without a molecular diagnosis despite extensive testing. Conventional assays typically target individual... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Each PhAST instrument supports random-access processing of up to four samples simultaneously, delivering a throughput of up to 12 samples per eight-hour shift. (Photo courtesy of PhAST)

FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures

Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.